<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928510</url>
  </required_header>
  <id_info>
    <org_study_id>15-001217</org_study_id>
    <secondary_id>NCI-2016-01002</secondary_id>
    <secondary_id>15-001217</secondary_id>
    <nct_id>NCT02928510</nct_id>
  </id_info>
  <brief_title>Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma</brief_title>
  <official_title>Idelalisib (GS-1101)-Associated Colitis - Molecular and Cellular Mechanisms Research Proposal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with&#xD;
      chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma&#xD;
      that has come back after a period of improvement. The cancer treatment drug idelalisib&#xD;
      triggers diarrhea in some patients. Studying stool, blood, and tissue samples in the lab from&#xD;
      patients who are given idelalisib may help doctors learn more about the side effects and may&#xD;
      help to treat them in future patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the cellular and molecular mechanisms of idelalisib-induced diarrhea/colitis in&#xD;
      relapsed chronic lymphocytic leukemia (CLL), relapsed indolent non-hodgkin lymphomas (iNHL),&#xD;
      or relapsed small lymphocytic lymphoma (SLL).&#xD;
&#xD;
      II. To further understand the mechanism of action (MOA) of idelalisib in context of the nodal&#xD;
      microenvironment and the possible involvement of the immune system in idelalisib's&#xD;
      anti-lymphoma activity.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6&#xD;
      biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy.&#xD;
      Patients receive idelalisib orally (PO) twice daily (BID) after visit 2. Treatment continues&#xD;
      in the absence of disease progression or unacceptable toxicity. A third research visit occurs&#xD;
      upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with&#xD;
      diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood&#xD;
      samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and&#xD;
      assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood&#xD;
      samples. All patients undergo optional biospecimen collection at the time of disease&#xD;
      progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    withdrawn by sponsor&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">June 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular mechanisms of idelalisib-induced diarrhea/colitis assessed by a number of tests in order to provide variability in comparisons for the units of measure.</measure>
    <time_frame>Up to 11 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Mechanism of Action (MOA) of idelalisib will be assessed with a number of tests in order to provide variability in comparisons for the units of measure.</measure>
    <time_frame>Up to 11 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Absence of Signs or Symptoms</condition>
  <condition>B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Digestive System Signs and Symptoms</condition>
  <condition>Indolent Adult Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Chronic Lymphocytic Leukemia</condition>
  <condition>Recurrent Indolent Adult Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
    <description>Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo biospecimen collection</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>Undergo colonoscopy</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colposcopic Biopsy</intervention_name>
    <description>Undergo colposcopic biopsy</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
    <other_name>CAL-101</other_name>
    <other_name>GS-1101</other_name>
    <other_name>Phosphoinositide-3 Kinase Delta Inhibitor CAL-101</other_name>
    <other_name>Zydelig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Examination</intervention_name>
    <description>Undergo physical examination</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
    <other_name>Assessment</other_name>
    <other_name>Physical</other_name>
    <other_name>Physical Assessment</other_name>
    <other_name>PHYSICAL EXAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sigmoidoscopy</intervention_name>
    <description>Undergo sigmoidoscopy</description>
    <arm_group_label>Basic Science (biospecimen collection, idelalisib)</arm_group_label>
    <other_name>Proctosigmoidoscopy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, stool and biopsies from sigmoidoscopy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from relapsed chronic lymphocytic leukemia (CLL), relapsed indolent&#xD;
        Non-Hodgkin lymphomas (iNHL), or relapsed small lymphocytic lymphoma (SLL) will be enrolled&#xD;
        in the UCLA Lymphoma Program and they will be receiving Idelalisib/Zydelig as the standard&#xD;
        care treatment are potentially eligible for this specimen collection study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Food and Drug Administration (FDA)-approved indications for idelalisib of relapsed,&#xD;
             histologically confirmed B-cell indolent non-hodgkin lymphoma (iNHL) or chronic&#xD;
             lymphocytic leukemia (CLL)&#xD;
&#xD;
          -  For iNHL: measureable nodal disease, defined as the presence of &gt;= 1 nodal lesion that&#xD;
             measures &gt;= 2 cm in a single dimension as assessed by computed tomography (CT) or&#xD;
             magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Discontinuation of all other therapies (including radiotherapy or chemotherapy) for&#xD;
             the treatment of iNHL &gt;= 3 weeks before initiation of study treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 750&#xD;
&#xD;
          -  Platelets &gt; 50,000&#xD;
&#xD;
          -  Total bilirubin &lt; 2 X institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate transaminase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/ alanine&#xD;
             transferase (ALT) serum glutamate pyruvate transaminase (SPGT) &lt; 3 X institutional ULN&#xD;
&#xD;
          -  Creatinine &lt; 2 X institutional ULN&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 90 days following completion of therapy;&#xD;
             should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she should inform her treating physician immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent; all&#xD;
             patients must have signed, witnessed informed consent prior to registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to idelalisib&#xD;
&#xD;
          -  Known histological transformation from iNHL to diffuse large B-cell lymphoma or&#xD;
             Richter's Transformation for CLL&#xD;
&#xD;
          -  Ongoing treatment with any other investigational agents&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement of lymphoma (CNS staging not required)&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to idelalisib&#xD;
&#xD;
          -  Uncontrolled inter-current illnesses including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection (HIV testing not required)&#xD;
&#xD;
          -  Known John Cunningham (JC) virus infection and/or progressive multifocal&#xD;
             leukoencephalopathy (PML)&#xD;
&#xD;
          -  Clinically active hepatitis A, B, or C infections&#xD;
&#xD;
          -  NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV)&#xD;
             infection may enroll if other laboratory criteria are met; those with HBV surface&#xD;
             antigen positivity may enroll only if maintained on appropriate suppressive antiviral&#xD;
             therapy for the duration of enrollment in the trial&#xD;
&#xD;
          -  Pregnancy or active nursing of an infant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Hommes</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

